Compared side by side
MK-677 vs CJC-1295 no DAC: how they differ
The short answer
They raise growth hormone through different receptors: MK-677 is a small molecule (not a peptide) that mimics ghrelin and is taken by mouth once a day, and CJC-1295 no DAC is a GHRH analogue injected 2–3 times a day for pulse-like GH release. MK-677’s effect on GH and IGF-1 lasts about a day, while the no-DAC form is short-acting. Commonly reported: strong hunger and water retention on MK-677, and a flush or head rush within minutes of injecting CJC-1295 no DAC.
Side by side
| Compared | MK-677 | CJC-1295 no DAC |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | Ibutamoren, Nutrobal, MK677, Ibutamoren Mesylate | Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC |
| What it is | Not actually a peptide — it's a small molecule you take orally that mimics ghrelin to stimulate GH release. | The shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release. |
| How it works | Orally active ghrelin receptor agonist and GH secretagogue. Stimulates GH and IGF-1 with little short-term effect on cortisol (a small rise over a year). Its long-lasting effect on GH and IGF-1 allows once-daily oral dosing. Significantly increases appetite and promotes deep sleep. MK-677 is a small molecule GH secretagogue, not a peptide — included because it is extremely commonly tracked alongside peptide GH protocols. | GHRH analogue without the DAC modification. Its half-life in people hasn't been measured (native GHRH lasts minutes), and the short action gives pulse-like GH release. Usually stacked with Ipamorelin to mimic natural GH secretion patterns. |
| Commonly reported | Strong hunger, especially in the first weeks; water retention with puffy hands and feet or tingling hands; and deeper sleep with vivid dreams, sometimes with morning grogginess. Once-daily dosing boosts natural GH pulses and keeps IGF-1 elevated. | A flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies. |
| Studied range | Research range: 10–25 mg, starting dose 10 mg. Studied in research — not a recommendation. | Research range: 100–200 mcg. Studied in research — not a recommendation. |
| How often | Daily, before bed | 2–3x daily |
| Half-life | ~24 hours (community estimate; no half-life has been published for people: in dogs it was 4–6 hours, and its effect on GH and IGF-1 lasts about a day) | ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes) |
| Route | Oral | SubQ injection |
| Typical run | Continuous use common (oral convenience). Some cycle 3 months on / 1 month off. Long-term safety data limited. | 8–12 weeks typical. Usually stacked with Ipamorelin; cycle both together. |
| Evidence | Moderate: animal studies + some human data | Moderate: animal studies + some human data |
| Common side effects | Increased appetite, water retention, lethargy, elevated fasting glucose, vivid dreams, carpal tunnel symptoms | Water retention, headache, flushing, injection site pain |
- Category
- MK-677Growth hormone
- CJC-1295 no DACGrowth hormone
- Also known as
- MK-677Ibutamoren, Nutrobal, MK677, Ibutamoren Mesylate
- CJC-1295 no DACModified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC
- What it is
- MK-677Not actually a peptide — it's a small molecule you take orally that mimics ghrelin to stimulate GH release.
- CJC-1295 no DACThe shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release.
- How it works
- MK-677Orally active ghrelin receptor agonist and GH secretagogue. Stimulates GH and IGF-1 with little short-term effect on cortisol (a small rise over a year). Its long-lasting effect on GH and IGF-1 allows once-daily oral dosing. Significantly increases appetite and promotes deep sleep. MK-677 is a small molecule GH secretagogue, not a peptide — included because it is extremely commonly tracked alongside peptide GH protocols.
- CJC-1295 no DACGHRH analogue without the DAC modification. Its half-life in people hasn't been measured (native GHRH lasts minutes), and the short action gives pulse-like GH release. Usually stacked with Ipamorelin to mimic natural GH secretion patterns.
- Commonly reported
- MK-677Strong hunger, especially in the first weeks; water retention with puffy hands and feet or tingling hands; and deeper sleep with vivid dreams, sometimes with morning grogginess. Once-daily dosing boosts natural GH pulses and keeps IGF-1 elevated.
- CJC-1295 no DACA flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies.
- Studied range
- MK-677Research range: 10–25 mg, starting dose 10 mg. Studied in research — not a recommendation.
- CJC-1295 no DACResearch range: 100–200 mcg. Studied in research — not a recommendation.
- How often
- MK-677Daily, before bed
- CJC-1295 no DAC2–3x daily
- Half-life
- MK-677~24 hours (community estimate; no half-life has been published for people: in dogs it was 4–6 hours, and its effect on GH and IGF-1 lasts about a day)
- CJC-1295 no DAC~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes)
- Route
- MK-677Oral
- CJC-1295 no DACSubQ injection
- Typical run
- MK-677Continuous use common (oral convenience). Some cycle 3 months on / 1 month off. Long-term safety data limited.
- CJC-1295 no DAC8–12 weeks typical. Usually stacked with Ipamorelin; cycle both together.
- Evidence
- MK-677Moderate: animal studies + some human data
- CJC-1295 no DACModerate: animal studies + some human data
- Common side effects
- MK-677Increased appetite, water retention, lethargy, elevated fasting glucose, vivid dreams, carpal tunnel symptoms
- CJC-1295 no DACWater retention, headache, flushing, injection site pain
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
MK-677
- Day 1–14 Hunger up, sleep deeper, water on
- Day 14–56 Lean mass is climbing
- Day 56–90 Check your labs — glucose is the watch item
CJC-1295 no DAC
- Day 1–14 Sleep usually moves first
- Day 14–28 Recovery is quicker, skin looks better
- Day 28–56 Body composition starts shifting
- Day 56–84 Cycle endpoint
Together or one or the other
MK-677 and CJC-1295 no DAC are a common stack: MK-677 lists CJC-1295 no DAC among its common stacks.
Questions people ask
How long do MK-677 and CJC-1295 no DAC last?
The half-life of MK-677 is ~24 hours (community estimate; no half-life has been published for people: in dogs it was 4–6 hours, and its effect on GH and IGF-1 lasts about a day). The half-life of CJC-1295 no DAC is ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes).
How often are MK-677 and CJC-1295 no DAC taken?
MK-677: daily, before bed. Route: Oral. CJC-1295 no DAC: 2–3x daily. Route: SubQ injection.
How are MK-677 and CJC-1295 no DAC dosed in research?
The research range for MK-677 is 10–25 mg, with a 10 mg starting dose. The research range for CJC-1295 no DAC is 100–200 mcg. Studied in research — not a recommendation.
What are the common side effects of MK-677 and CJC-1295 no DAC?
For MK-677, the library lists: increased appetite, water retention, lethargy, elevated fasting glucose, vivid dreams, carpal tunnel symptoms. For CJC-1295 no DAC: water retention, headache, flushing, injection site pain.
Are MK-677 and CJC-1295 no DAC taken together?
MK-677 and CJC-1295 no DAC are a common stack: MK-677 lists CJC-1295 no DAC among its common stacks.